JADE BIOSCIENCES INC (JBIO) Stock Fundamental Analysis

NASDAQ:JBIO • US0080642061

14.56 USD
+0.06 (+0.41%)
At close: Feb 26, 2026
14.3 USD
-0.26 (-1.79%)
After Hours: 2/26/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to JBIO. JBIO was compared to 521 industry peers in the Biotechnology industry. While JBIO has a great health rating, there are worries on its profitability. JBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year JBIO has reported negative net income.
  • JBIO had a negative operating cash flow in the past year.
  • In the past 5 years JBIO always reported negative net income.
  • JBIO had a negative operating cash flow in each of the past 5 years.
JBIO Yearly Net Income VS EBIT VS OCF VS FCFJBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of JBIO (-32.23%) is better than 64.30% of its industry peers.
  • With a decent Return On Equity value of -36.39%, JBIO is doing good in the industry, outperforming 71.98% of the companies in the same industry.
Industry RankSector Rank
ROA -32.23%
ROE -36.39%
ROIC N/A
ROA(3y)-61.34%
ROA(5y)-80.96%
ROE(3y)-66.92%
ROE(5y)-110.13%
ROIC(3y)N/A
ROIC(5y)N/A
JBIO Yearly ROA, ROE, ROICJBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • JBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JBIO Yearly Profit, Operating, Gross MarginsJBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for JBIO has been increased compared to 1 year ago.
  • The number of shares outstanding for JBIO has been increased compared to 5 years ago.
  • JBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JBIO Yearly Shares OutstandingJBIO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
JBIO Yearly Total Debt VS Total AssetsJBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • JBIO has an Altman-Z score of 17.66. This indicates that JBIO is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 17.66, JBIO belongs to the top of the industry, outperforming 88.10% of the companies in the same industry.
  • JBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.66
ROIC/WACCN/A
WACCN/A
JBIO Yearly LT Debt VS Equity VS FCFJBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 9.01 indicates that JBIO has no problem at all paying its short term obligations.
  • The Current ratio of JBIO (9.01) is better than 78.50% of its industry peers.
  • A Quick Ratio of 9.01 indicates that JBIO has no problem at all paying its short term obligations.
  • The Quick ratio of JBIO (9.01) is better than 78.50% of its industry peers.
Industry RankSector Rank
Current Ratio 9.01
Quick Ratio 9.01
JBIO Yearly Current Assets VS Current LiabilitesJBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 89.35% over the past year.
EPS 1Y (TTM)89.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, JBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.45% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.51%
EPS Next 2Y40.61%
EPS Next 3Y25.47%
EPS Next 5Y14.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JBIO Yearly EPS VS EstimatesJBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • JBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year JBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JBIO Price Earnings VS Forward Price EarningsJBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JBIO Per share dataJBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as JBIO's earnings are expected to grow with 25.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.61%
EPS Next 3Y25.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 558.88%, JBIO is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.17, JBIO pays a better dividend. On top of this JBIO pays more dividend than 100.00% of the companies listed in the same industry.
  • JBIO's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 558.88%

5.2 History

  • JBIO is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
JBIO Yearly Dividends per shareJBIO Yearly Dividends per shareYearly Dividends per share 2025 20 40 60 80

5.3 Sustainability

DPN/A
EPS Next 2Y40.61%
EPS Next 3Y25.47%
JBIO Yearly Income VS Free CF VS DividendJBIO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 -20M -40M -60M

More info and screens

Find the best dividend stocksShow peers with best dividend

JADE BIOSCIENCES INC

NASDAQ:JBIO (2/26/2026, 8:00:02 PM)

After market: 14.3 -0.26 (-1.79%)

14.56

+0.06 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners78.88%
Inst Owner Change43.86%
Ins Owners1.06%
Ins Owner Change29.77%
Market Cap717.95M
Revenue(TTM)N/A
Net Income(TTM)-65.26M
Analysts88.57
Price Target22.44 (54.12%)
Short Float %3.09%
Short Ratio4.39
Dividend
Industry RankSector Rank
Dividend Yield 558.88%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.33%
Min EPS beat(2)-94.83%
Max EPS beat(2)30.18%
EPS beat(4)3
Avg EPS beat(4)6.02%
Min EPS beat(4)-94.83%
Max EPS beat(4)63.24%
EPS beat(8)4
Avg EPS beat(8)2.3%
EPS beat(12)5
Avg EPS beat(12)0.37%
EPS beat(16)5
Avg EPS beat(16)-5.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.55%
EPS NY rev (1m)0%
EPS NY rev (3m)11.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4
P/tB 4
EV/EBITDA N/A
EPS(TTM)-11.14
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0
BVpS3.64
TBVpS3.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.23%
ROE -36.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.34%
ROA(5y)-80.96%
ROE(3y)-66.92%
ROE(5y)-110.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.01
Quick Ratio 9.01
Altman-Z 17.66
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
EPS Next Y96.51%
EPS Next 2Y40.61%
EPS Next 3Y25.47%
EPS Next 5Y14.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.82%
OCF growth 3YN/A
OCF growth 5YN/A

JADE BIOSCIENCES INC / JBIO FAQ

What is the fundamental rating for JBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to JBIO.


What is the valuation status for JBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to JADE BIOSCIENCES INC (JBIO). This can be considered as Overvalued.


Can you provide the profitability details for JADE BIOSCIENCES INC?

JADE BIOSCIENCES INC (JBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for JBIO stock?

The financial health rating of JADE BIOSCIENCES INC (JBIO) is 8 / 10.